Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19875057 | 0.74 | RPS6KB2 (0.32) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL19875003 | 0.74 | RPS6KB2 (0.32) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL2290788 | 0.72 | FBP1 (0.36) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL20550992 | 0.72 | FBP1 (0.36) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL2341397 | 0.72 | — | — | |
| SCHEMBL8912674 | 0.71 | FBP1 (0.39) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL29266739 | 0.70 | MEN1 (0.38) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL19874981 | 0.70 | DPP4 (0.33) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL8983864 | 0.68 | — | — | |
| SCHEMBL9190818 | 0.68 | ALDH1A1 (0.33) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119751269-A | Synthesis technology for preparing alpha-deuterated amine compound | 郑州大学 | 2025-04-04 | — | — | CN | claimed |
| CN-119490396-A | Synthetic technology for preparing deuterated aldehyde compound | 郑州大学 | 2025-02-21 | — | — | CN | claimed |
| US-20150112028-A1 | SYNTHESIS OF CHALOGEN-CAPPED PI-CONJUGATED POLYMERS | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-04-23 | — | — | US | claimed |
| CN-118344244-A | Preparation method of deuterated compound based on alkyl alcohol | 大连理工大学 | 2024-07-16 | — | — | CN | disclosed |
| EP-3416956-B1 | METHYLAMINE DERIVATIVES AS LYSYL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-04-10 | — | — | EP | disclosed |
| EP-4267567-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2023-11-01 | — | — | EP | disclosed |
| EP-4240869-A1 | METHODS FOR DETECTION OF NUCLEOTIDE MODIFICATION | Bluecat IP Limited (GB) | 2023-09-13 | — | — | EP | disclosed |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2023-03-21 | — | — | US | disclosed |
| US-20230014870-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2023-01-19 | — | — | US | disclosed |
| WO-2022136307-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-06-30 | — | — | WO | disclosed |
| CN-114555620-A | Novel galactoside inhibitors of galectins | 格莱克特生物技术公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2002083694-A1 | SYNTHESIS OF SILYL CAMPTOTHECINS AND SILYL HOMOCAMPTOTHECINS | UNIVERSITY OF PITTSBURGH (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-1214296-A1 | SUBSTITUTED N-PHENYL 2-HYDROXY-2-METHYL-3,3,3-TRIFLUOROPROPANAMIDE DERIVATIVES WHICH ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY | AstraZeneca AB (SE) | 2002-06-19 | — | — | EP | disclosed |
| US-6372906-B1 | REACTING CAMPTOTHECIN OR HOMOCAMPTOTHECIN WITH SILYL RADICAL PRECURSOR UNDER CONDITIONS TO GENERATE SILYL RADICAL | UNIVERSITY OF PITTSBURGH | 2002-04-16 | — | — | US | disclosed |
| EP-1165505-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1140814-A2 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-10-10 | — | — | EP | disclosed |
| CN-1303281-A | Application of compound in enhancing activity of pyruvate dehydrogenase | ASTRA ZENECA LTD (SE) | 2001-07-11 | — | — | CN | disclosed |
| WO-2001017956-A1 | SUBSTITUTED N-PHENYL 2-HYDROXY-2-METHYL-3,3,3-TRIFLUOROPROPANAMIDE DERIVATIVES WHICH ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000059880-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000039081-A2 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014870-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | ALDH1A1 979/4885HPGD 2942/4885SMN1; SMN2 4741/4885 |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | ALDH1A1 2293/4885HPGD 1373/4885SMN1; SMN2 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.